The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new Bronchiectasis and NTM Care Center ...

The Bronchiectasis and NTM Association has accepted UC San Francisco (UCSF) into its Bronchiectasis and NTM Care Center Network (CCN), recognizing UCSF’s dedication to providing high-quality medical ...

Prior to being diagnosed with bronchiectasis, many patients reported living with symptoms for multiple years, according to ...

According to PROMIS-I data published in the journal of The Lancet Respiratory Medicine showed that individuals with ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

and a study assessing the safety and efficacy of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis (“bronchiectasis”). We are pleased to report the glycopyrrolate dose-ranging ...

Insmed Incorporated (NASDAQ: INSM) announced on February 24, 2025 that the U.S. Food and Drug Administration (FDA) does not currently plan to hold an advisory committee meeting to discuss the ...

RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.

Background: Little information is available regarding whether active physical activity lowers mortality risk in individuals with bronchiectasis. Methods: We used the Korean National Health Insurance ...

This Phase 3 study is the largest ever conducted for bronchiectasis, a chronic lung condition characterized by the widening of the airways, leading to recurrent infections, inflammation ...

today announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome (PRO ...